Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Diabetes & Metabolism Journal|July 29, 2026
Efficacy and Safety of the Dual SGLT1 and SGLT2 Inhibitor JP-2266 in Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 StudyEun Young Lee, Kyung Ah Han, Soo Heon Kwak, et al.
Diabetes & Metabolism Journal|December 27, 2014
GDF15 Is a Novel Biomarker for Impaired Fasting GlucoseJun Hwa Hong, Hyo Kyun Chung, Hye Yoon Park, et al.
Diabetes, Obesity & Metabolism|February 3, 2026
Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy (EFFORT): A 24-week, randomized, open-label, multicenter trialSo Ra Kim, Jun Hwa Hong, Sin Gon Kim, et al.
Cancer Letters|July 18, 2015
Colorectal cancer-derived tumor spheroids retain the characteristics of original tumorsSun-Hwa Lee, Jun Hwa Hong, Hwan Ki Park, et al.
Diabetes & Metabolism Journal|March 6, 2018
Patient Understanding of Hypoglycemia in Tertiary Referral CentersNan Hee Cho, Nam Kyung Kim, Eugene Han, et al.
Clinical Therapeutics|July 27, 2024
Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled StudyYun Kyung Cho, Kyung-Soo Kim, Byung-Wan Lee, et al.
Diabetes & Metabolism Journal|December 17, 2025
Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical TrialYong-Ho Lee, Kyung Wan Min, Jun Hwa Hong, et al.
Journal of Korean Medical Science|April 26, 2008
Regulation of inhibitors of differentiation family proteins by thyroid-stimulating hormone in FRTL-5 thyroid cellsYoung Suk Jo, Eun Suk Hwang, Ju Hee Lee, et al.
Diabetes & Metabolism Journal|October 28, 2025
Efficacy and Safety of High-Dose Pioglitazone as Add-on Therapy in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Dapagliflozin and Metformin: Double-Blind, Randomized, Placebo-Controlled TrialJun Hwa Hong, Kyung Ah Han, You-Cheol Hwang, et al.
Diabetes & Metabolism Journal|December 15, 2025
Efficacy and Safety of Enavogliflozin as Add-on in Adults with Type 2 Diabetes Mellitus Inadequately Controlled with Insulin or Insulin with Other Antidiabetic DrugsJun Hwa Hong, Kyung Wan Min, Chang Beom Lee, et al.
Pageof 4